New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 29, 2014
07:35 EDTNBSNeoStem presents five-year survival data for autologous melanoma Immunotherapy
NeoStem announced results of a pooled analysis indicating that Melapuldencel-T, an investigational patient-specific immunotherapy for metastatic melanoma, may increase survival rates significantly for patients at the most advanced stages of the disease. The findings will be presented on Sunday, June 1 in a poster by Robert O. Dillman, MD, study author and Vice-President, NeoStem Oncology, at the 50th Annual Meeting of the American Society of Clinical Oncology, or ASCO. The analysis to be presented at ASCO includes a subset of pooled data from three melanoma clinical trials, conducted successively from 1990-2011. Two of these trials, one of which was controlled and one of which was not, studied Melapuldencel-T. The new pooled analysis indicates significantly better five-year overall survival rates in patients treated with Melapuldencel-T than those treated with the comparator therapy for the subset of patients who still had evidence of disease after prior treatment with one or more standard therapies. "This subset analysis lends further support to the view that tumor-initiating cells are viable targets for therapeutic interventions like Melapuldencel-T, aiming for better overall survival, even for patients in the most advanced stages of malignant melanoma. In addition, the product may have significant safety and tolerability advantages over existing therapies," said Dr. Dillman. Chief Medical Officer Douglas Losordo, said, "NeoStem is excited to continue investigating this promising therapy in a large-scale Phase 3 study beginning this year." Melapuldencel-T was developed by California Stem Cell, Inc., which was acquired by NeoStem in May. NeoStem is initiating a Phase 3 study of Melapuldencel-T later this year under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration, and the therapy has been granted fast-track designation by the agency as well.
News For NBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
15:26 EDTNBSNeoStem provides info on the design of the Phase 2 PreSERVE AMI trial
Subscribe for More Information
November 19, 2014
07:09 EDTNBSJefferies to hold a conference
2014 Global London Healthcare Conference is being held in London, England on November 19-20.
November 18, 2014
09:20 EDTNBSOn The Fly: Pre-market Movers
Subscribe for More Information
07:20 EDTNBSNeoStem volatility elevated into presenting data
Subscribe for More Information
07:09 EDTNBSNeoStem to host conference call
Subscribe for More Information
November 17, 2014
18:32 EDTNBSOn The Fly: After Hours Movers
Subscribe for More Information
17:18 EDTNBSNeoStem announces initial positive data from Phase 2 PreSERVE AMI clinical trial
NeoStem announced initial positive data from its 161 patient Phase 2 PreSERVE AMI,or acute myocardial infarction, clinical trial. These data are based on all enrolled patients being treated and having received six month follow-up for imaging and twelve month median length follow up for mortality, adverse events, serious adverse events, SAEs, and major adverse cardiac events, MACE."For cardiologists, our key goal is to keep patients from progressing to worsening heart muscle function and death after a major heart attack," said Dr. Arshed A. Quyyumi, Professor of Medicine at Emory University and Lead Principal Investigator of the PreSERVE AMI study. "It is encouraging to see clinically meaningful results this early in the study, and I look forward to future data readouts."
11:11 EDTNBSHigh option volume stocks:
Subscribe for More Information
November 14, 2014
10:00 EDTNBSOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AbbVie (ABBV) initiated with a Buy at Deutsche Bank... Advance Auto Parts (AAP) initiated with a Buy at Sterne Agee... AutoZone (AZO) initiated with an Underperform at Sterne Agee... Carter's (CRI) initiated with a Buy at Sterne Agee... Children's Place (PLCE) initiated with a Neutral at Sterne Agee... Container Store (TCS) initiated with a Fair Value at CRT Capital... DHT Holdings (DHT) initiated with a Buy at UBS... Diana Shipping (DSX) initiated with a Neutral at UBS... Genuine Parts (GPC) initiated with a Neutral at Sterne Agee... National Oilwell (NOV) initiated with a Neutral at UBS... Navios Acquisition (NNA) initiated with a Buy at UBS... NeoStem (NBS) assumed with a Buy at Maxim... O'Reilly Automotive (ORLY) initiated with a Neutral at Sterne Agee... Scorpio Bulkers (SALT) initiated with a Neutral at UBS... Star Bulk Carriers (SBLK) initiated with a Neutral at UBS... Teekay Tankers (TNK) initiated with a Buy at UBS... The Buckle (BKE) initiated with an Underweight at BB&T... TriMas (TRS) initiated with an Overweight at JPMorgan... TriplePoint Venture (TPVG) initiated with a Buy at UBS... Tsakos Energy (TNP) initiated with a Buy at UBS... USD Partners (USDP) initiated with an Outperform at Credit Suisse... Zumiez (ZUMZ) initiated with a Buy at BB&T.
09:07 EDTNBSNeoStem assumed with a Buy at Maxim
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use